Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

Fintel reports that on October 16, 2024, HC Wainwright & Co. upgraded their outlook for NovoCure (NasdaqGS:NVCR) from Neutral ...

NovoCure shows mixed results in NSCLC, strong financially but cautious sell recommendation due to limited progress outside ...

The US Food and Drug Administration (FDA) has approved Novocure's Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

“Novocure is committed to extending ... cancer-related death worldwide1, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. It is estimated that ...

Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small ... any or all of these forward ...

Highlights:,Significant Stock Surge:,NovoCure's shares rose by 10.7% to $17.78, driven by substantial trading volume following FDA approval of its Optune Lua device for metastatic non-small cell lung ...

Lung cancer remains the leading cause of cancer-related death worldwide, with NSCLC accounting for approximately 85% of all ... Novocure. The FDA approval of Optune Lua for metastatic non-small ...

Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call ...